Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 12/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16556851 | 0.91 | IGF1R (0.46) | NTRK1IGF1RFLT3GSK3AGSK3B | |
| SCHEMBL16556920 | 0.91 | IGF1R (0.46) | NTRK1IGF1RFLT3 | |
| SCHEMBL10312150 | 0.91 | IGF1R (0.48) | NTRK1IGF1RFLT3 | |
| SCHEMBL10312190 | 0.90 | MELK (0.44) | NTRK1IGF1RFLT3 | |
| SCHEMBL10312201 | 0.88 | FLT3 (0.46) | NTRK1IGF1RFLT3PLK4POLB | |
| SCHEMBL10312199 | 0.87 | FLT3 (0.45) | FLT3POLBGSK3AGSK3BGRK6 | |
| SCHEMBL10312093 | 0.86 | IGF1R (0.43) | NTRK1IGF1RPLK4 | |
| SCHEMBL10312157 | 0.83 | IGF1R (0.47) | IGF1RPLK4 | |
| SCHEMBL10312211 | 0.80 | IGF1R (0.50) | NTRK1IGF1RPLK4GSK3B | |
| SCHEMBL10312118 | 0.79 | FLT3 (0.46) | NTRK1IGF1RFLT3PLK4GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | NTRK1 482/4885IGF1R 1148/4885FLT3 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.